Edwards Lifesciences Corp (NYSE: EW) has a higher price-to-earnings ratio of 10.25x compared to its average ratio. EW has 36-month beta value of 1.11. Analysts have mixed views on the stock, with 9 analysts rating it as a “buy,” 5 as “overweight,” 19 as “hold,” and 0 as “sell.”
The public float for EW is 579.56M, and currently, short sellers hold a 1.95% ratio of that float. The average trading volume of EW on January 14, 2025 was 4.99M shares.
EW) stock’s latest price update
Edwards Lifesciences Corp (NYSE: EW)’s stock price has plunge by -3.17relation to previous closing price of 73.42. Nevertheless, the company has seen a -3.82% plunge in its stock price over the last five trading sessions. businesswire.com reported 2025-01-07 that IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived v.
EW’s Market Performance
Edwards Lifesciences Corp (EW) has experienced a -3.82% fall in stock performance for the past week, with a -3.13% drop in the past month, and a 4.15% rise in the past quarter. The volatility ratio for the week is 2.05%, and the volatility levels for the past 30 days are at 2.12% for EW. The simple moving average for the last 20 days is -3.88% for EW stock, with a simple moving average of -7.74% for the last 200 days.
Analysts’ Opinion of EW
Morgan Stanley, on the other hand, stated in their research note that they expect to see EW reach a price target of $70. The rating they have provided for EW stocks is “Equal-Weight” according to the report published on October 11th, 2024.
Jefferies gave a rating of “Hold” to EW, setting the target price at $70 in the report published on September 18th of the previous year.
EW Trading at -0.16% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.04% of loss for the given period.
Volatility was left at 2.12%, however, over the last 30 days, the volatility rate increased by 2.05%, as shares sank -3.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.48% upper at present.
During the last 5 trading sessions, EW fell by -3.82%, which changed the moving average for the period of 200-days by -23.90% in comparison to the 20-day moving average, which settled at $73.96. In addition, Edwards Lifesciences Corp saw -3.97% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EW starting from Lippis Daniel J., who sale 2,500 shares at the price of $74.08 back on Dec 16 ’24. After this action, Lippis Daniel J. now owns 23,189 shares of Edwards Lifesciences Corp, valued at $185,196 using the latest closing price.
Lippis Daniel J., the Officer of Edwards Lifesciences Corp, proposed sale 2,500 shares at $74.08 during a trade that took place back on Dec 16 ’24, which means that Lippis Daniel J. is holding shares at $185,196 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.78 for the gross margin
The net margin for Edwards Lifesciences Corp stands at 0.71. The total capital return value is set at 0.14. Equity return is now at value 17.93, with 13.01 for asset returns.
Based on Edwards Lifesciences Corp (EW), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 1.14. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 57.44.
Currently, EBITDA for the company is 1.77 billion with net debt to EBITDA at -1.74. When we switch over and look at the enterprise to sales, we see a ratio of 6.63. The receivables turnover for the company is 7.24for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.46.
Conclusion
To put it simply, Edwards Lifesciences Corp (EW) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
